PRINCETON, NJ -- (MARKET WIRE) -- March 06, 2007 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company focused on the development and commercialization of products in the field of dermatology, today announced that it has entered into an agreement with Novartis Consumer Health, Inc. whereby Novartis Consumer Health will promote Barrier Therapeutics’ Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment to pediatricians in the U.S.
